Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

​

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section and Professor of Medicine at Columbia University Medical Center, has initiated Actimab-A MRD, a new clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).  The trial will study the safety/tolerability of Actimab-A in the postremission consolidation setting and include dose finding analyses.  The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The investigational new drug (IND) application for this trial has been cleared by the FDA.

Together with Dr. Jurcic, Actinium will host a webcast to discuss the planned trial, participation information is as follows:

Date: July 10, 2018

Time: 8:00 AM ET

Registration Link: https://onecast.thinkpragmatic.com/ses/qkRLz4ale4gPNiJMuSsxQg~~

Telephone participation: U.S./Canada Toll Free: (855) 427-0225 or (718) 865-8336

Conference ID: 2540

To read more please visit: https://www.nasdaq.com/press-release/actinium-announces-new-clinical-trial-to-study-effect-of-actimaba-on-minimal-residual-disease-in-20180628-00398

Source: Nasdaq